Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,359 across all filing types
Latest filing 2026-05-28 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
北京市中勤律师事务所关于亚宝药业集团股份有限公司2025年度股东会律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a lawyer’s legal opinion letter (见证法律意见书) covering the convening, attendance and detailed voting results of the 2025 annual general shareholders’ meeting, including vote counts, percentages and confirmation of resolution validity. This aligns with Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official vote outcomes from shareholder meetings.
2026-05-28 Chinese
亚宝药业集团股份有限公司关于董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an official announcement (“公告”) from 亚宝药业 regarding the re-election (换届选举) of its board of directors, detailing the nomination of non-independent and independent director candidates and their resumes. This clearly fits the definition of a Board/Management Information filing, which covers announcements of changes in the company’s board of directors or senior management. There is no substantive financial data or other report attached; it is purely a board election announcement.
2026-05-28 Chinese
亚宝药业独立董事提名人声明与承诺（二）
Board/Management Information Classification · 15% confidence The document is a formal nomination and declaration by the company’s board nominating an independent director candidate and detailing qualification and independence requirements. It relates to board composition changes (independent director nomination) rather than financial results or regulatory filings. Therefore it falls under Board/Management Information (MANG).
2026-05-28 Chinese
亚宝药业独立董事提名人声明与承诺（一）
Board/Management Information Classification · 80% confidence The document is a public disclosure by a company’s board nominating candidates for independent director positions. It outlines nominee qualifications, commitments, and regulatory compliance, and is part of board-level management changes (nomination) rather than a full annual report, financial statement, or earnings release. This fits the Board/Management Information category.
2026-05-28 Chinese
亚宝药业集团股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an announcement of the outcome of the 2025 Annual General Meeting of shareholders, detailing the votes cast on each resolution, vote counts and percentages, and legal witness statements. This matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA). It is not a full annual report, management discussion, or investor presentation, but specifically the formal voting results of an AGM.
2026-05-28 Chinese
亚宝药业集团股份有限公司关于参加山西辖区上市公司2026年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 48% confidence The document is a public announcement (“公告”) that the company will participate in an online investor reception day and annual performance briefing event, rather than the presentation materials themselves. It contains no substantive financial data or actual slides but rather an event notice. This fits the general regulatory announcement/fallback category (RNS).
2026-05-15 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.